{"classes":[{"categories":[{"measurements":[{"comment":"not reached","groupId":"OG000","lowerLimit":"9.3","upperLimit":"NA","value":"16.8"},{"comment":"not reached","groupId":"OG001","lowerLimit":"13.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"Overall survival per treatment arm. Overall survival is defined as the time from start of treatment to death of any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II: Pomalidomide and high dose dexamethasone.\n\nCrossover Arm D is a part of Arm B. Arm D was opened later to accommodate requested transfers from Arm B. Participants who experienced progressive disease in arm B were allowed to crossover to arm D at the discretion of the treating physician.\n\nArm D participants may be referenced separately in some Outcome Measures.","id":"OG000","title":"B: Pomalidomide and Dexamethasone"},{"description":"Phase II: Pomalidomide high dose dexamethasone and oral cyclophosphamide.","id":"OG001","title":"C: Pomalidomide, Dexamethasone, Cyclophosphamide"}],"paramType":"MEDIAN","populationDescription":"All participants assigned to Arm B and Arm C.","reportingStatus":"POSTED","timeFrame":"36 Months","title":"Phase II - Median Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}